Trials / Completed
CompletedNCT02523365
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma
HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Cervical Carcinoma: Clinical Trial
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- Fuda Cancer Hospital, Guangzhou · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for cervical carcinoma.
Detailed description
By enrolling patients with cervical carcinoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography（DSA） for cervical carcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | interventional therapy | cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA） |
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2016-08-01
- Completion
- 2016-08-01
- First posted
- 2015-08-14
- Last updated
- 2016-08-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02523365. Inclusion in this directory is not an endorsement.